IN2013DE00228A - “recombinant human paraoxonase 1 enzymes, method of generation and uses thereof” - Google Patents

“recombinant human paraoxonase 1 enzymes, method of generation and uses thereof” Download PDF

Info

Publication number
IN2013DE00228A
IN2013DE00228A IN228/DEL/2013A IN228DE2013A IN2013DE00228A IN 2013DE00228 A IN2013DE00228 A IN 2013DE00228A IN 228DE2013 A IN228DE2013 A IN 228DE2013A IN 2013DE00228 A IN2013DE00228 A IN 2013DE00228A
Authority
IN
India
Prior art keywords
enzymes
molecules
recombinant human
pro
present
Prior art date
Application number
IN228/DEL/2013A
Inventor
H Pande Abhay
Bajaj Priyanka
K Tripathy Rajan
Agrawal Geetika
Original Assignee
Nat Inst Of Pharmaceutical Education And Res Niper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Inst Of Pharmaceutical Education And Res Niper filed Critical Nat Inst Of Pharmaceutical Education And Res Niper
Priority to IN228/DEL/2013A priority Critical patent/IN2013DE00228A/en
Priority to PCT/IB2014/058461 priority patent/WO2014115084A2/en
Publication of IN2013DE00228A publication Critical patent/IN2013DE00228A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/08—Phosphoric triester hydrolases (3.1.8)
    • C12Y301/08001—Aryldialkylphosphatase (3.1.8.1), i.e. paraoxonase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01002—Arylesterase (3.1.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides novel polynucleotide sequences encoding recombinant human paraoxonase 1 enzymes, having enhanced catalytic activities towards a wide range of substrates including pro-atherogenic and pro-inflammatory molecules, quorum sensors and neurotoxic organophosphorus compounds, for high level expression in Escherichia coli. The invention also provides a novel method to produce the recombinant enzymes in highly pure and active form in high yield by refolding the recombinant enzymes from the inclusion. The molecules disclosed in the present invention can be used as therapeutic agents against PON1-associated disease or conditions. The molecules can also be used as detoxifying and decontaminating agents in numerous terrorist, drug, and environmental scenarios involving military and civilian welfare.
IN228/DEL/2013A 2013-01-28 2013-01-28 “recombinant human paraoxonase 1 enzymes, method of generation and uses thereof” IN2013DE00228A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN228/DEL/2013A IN2013DE00228A (en) 2013-01-28 2013-01-28 “recombinant human paraoxonase 1 enzymes, method of generation and uses thereof”
PCT/IB2014/058461 WO2014115084A2 (en) 2013-01-28 2014-01-22 Recombinant human paraoxonase 1 enzymes, method of generation and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN228/DEL/2013A IN2013DE00228A (en) 2013-01-28 2013-01-28 “recombinant human paraoxonase 1 enzymes, method of generation and uses thereof”

Publications (1)

Publication Number Publication Date
IN2013DE00228A true IN2013DE00228A (en) 2015-06-19

Family

ID=51228148

Family Applications (1)

Application Number Title Priority Date Filing Date
IN228/DEL/2013A IN2013DE00228A (en) 2013-01-28 2013-01-28 “recombinant human paraoxonase 1 enzymes, method of generation and uses thereof”

Country Status (2)

Country Link
IN (1) IN2013DE00228A (en)
WO (1) WO2014115084A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110387380B (en) * 2019-07-09 2021-05-04 武汉华肽生物科技有限公司 Production method of gene recombinant protein Tat-hMsrA
CN113621686A (en) * 2021-08-11 2021-11-09 海南微氪生物科技股份有限公司 Detection method suitable for various pathogenic microorganisms
CN114609216B (en) * 2022-03-25 2024-03-19 内江师范学院 beta-CD modified electrode, preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007105223A2 (en) * 2006-03-16 2007-09-20 Yeda Research And Development Co. Ltd. Methods of diagnosing pon1-hdl associated lipid disorders
US8735124B2 (en) * 2009-09-17 2014-05-27 Yeda Research And Development Co. Ltd. Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage

Also Published As

Publication number Publication date
WO2014115084A3 (en) 2014-11-20
WO2014115084A2 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
PE20151727A1 (en) 2-AZA-BICYCLE ACID [2.2.1] HEPTANE-3-CARBOXYL (BENZYL-CYAN-METHYL) -AMIDES SUBSTITUTED, CATEPSIN C INHIBITORS
MX2018001567A (en) Novel fusion polypeptide specific for lag-3 and pd-1.
EA201990665A1 (en) HPK1 REGULATORS BASED ON PYRAZOLOPYRIDINE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF CANCER
IN2014DN09782A (en)
BR112015010955A2 (en) heterocyclic glutaminase inhibitors
MY156188A (en) Long - acting formulations of insulins
CY1118934T1 (en) PREPARATION OF EXTREMELY PHOSPHORLILENED N-ACETYLGACTOZAMINE-6-SULFATHASE ACTIVITY AND USES thereof
TR201908163T4 (en) Pyrazolopyridine derivatives as modulators of Tnf activity.
NZ749911A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
JO3357B1 (en) Imidazopyrrolidinone compounds
CL2015001241A1 (en) Use of interleukin 2 (il-2) to treat inflammatory or autoimmune-related disorders (div. Sol. No. 2608-13)
TN2013000427A1 (en) Modified acid alpha glucosidase with accelerated processing
ES2694667T3 (en) Method for producing oxalate oxidases having optical activity near physiological pH and use of such recombinant oxalate oxidases in the treatment of oxalate-related diseases
MX2016000794A (en) High potency pancreatin pharmaceutical compositions.
EA201491155A1 (en) NEW MUTANT PRO-NRF AND THEIR APPLICATION TO GET BETA-NRF
BR112015013349A2 (en) trieptanoin for the treatment of glucose transporter deficiency 1
UA113849C2 (en) THE APPLICATION OF SIGMA LIGANDS IN TYPE 2 PATIENTS WITH PAIN
GEP201706621B (en) Benzamides
EA201201617A1 (en) APPLICATION OF METMORPHINE IN COMBINATION WITH GLUCOKINASE ACTIVATOR AND COMPOSITIONS CONTAINING METMORPHIN AND GLUCOKINASE ACTIVATOR
MX2018002223A (en) Novel insulin derivatives and the medical uses hereof.
GB201206486D0 (en) Vesicular formulations and uses thereof
EA201991877A3 (en) 7-BENZyl-4- (2-methylbenzyl) -2,4,6,7,8,9-hexahydroimidazo [1,2-A] pyrido [3,4-E] pyrimidine-5 (1H) -OH, its SALTS AND APPLICATIONS
EA201491369A1 (en) METHOD OF TREATING DIABETES MELLITUS WITH NON-GLYCOLYNED APOLYPOPROTEIN A-IV
IN2013DE00228A (en) “recombinant human paraoxonase 1 enzymes, method of generation and uses thereof”
BR112015010223A2 (en) tricyclic compounds for use in the treatment and / or control of obesity